Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
3.240
-0.100 (-2.99%)
At close: Mar 6, 2026, 4:00 PM EST
3.170
-0.070 (-2.16%)
After-hours: Mar 6, 2026, 4:48 PM EST
Imunon Employees
Imunon had 25 employees as of December 31, 2024. The number of employees decreased by 8 or -24.24% compared to the previous year.
Employees
25
Change (1Y)
-8
Growth (1Y)
-24.24%
Revenue / Employee
n/a
Profits / Employee
-$573,176
Market Cap
11.02M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 61 |
| CytoMed Therapeutics | 43 |
| Longeveron | 25 |
| Moleculin Biotech | 17 |
| Soligenix | 16 |
| CalciMedica | 15 |
| Cellectar Biosciences | 11 |
| Akari Therapeutics, | 9 |
IMNN News
- 4 weeks ago - IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY - GlobeNewsWire
- 2 months ago - IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules - GlobeNewsWire
- 2 months ago - IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026 - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript - Seeking Alpha
- 4 months ago - IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer - GlobeNewsWire
- 4 months ago - IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer - GlobeNewsWire